Showing results (11-20 of 66) with videos related to
Sort By:
Pageof 7
Biochemical and Biophysical Research Communications|November 17, 2006
Long term low-dose arsenic exposure induces loss of DNA methylationJohn F Reichard, Michael Schnekenburger, Alvaro PugaBiochemical Pharmacology|November 11, 2019
Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemiaManon Lernoux, Michael Schnekenburger, Mario Dicato, et al.Cancer Letters|October 2, 2013
Antiproliferative and proapoptotic activities of 4-hydroxybenzoic acid-based inhibitors of histone deacetylasesCarole Seidel, Michael Schnekenburger, Mario Dicato, et al.Biochemical Pharmacology|March 20, 2021
Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitorsManon Lernoux, Michael Schnekenburger, Mario Dicato, et al.Biochemical Pharmacology|February 21, 2012
MicroRNAs in cancer management and their modulation by dietary agentsTommy Karius, Michael Schnekenburger, Mario Dicato, et al.Annals of the New York Academy of Sciences|January 22, 2005
GATA-1: friends, brothers, and coworkersFranck Morceau, Michael Schnekenburger, Mario Dicato, et al.Pharmacological Research|November 15, 2017
Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathwaysManon Lernoux, Michael Schnekenburger, Mario Dicato, et al.Molecules (Basel, Switzerland)|November 26, 2016
Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in CancerHélène Losson, Michael Schnekenburger, Mario Dicato, et al.Genes & Nutrition|February 14, 2012
Histone deacetylase modulators provided by Mother NatureCarole Seidel, Michael Schnekenburger, Mario Dicato, et al.Current Topics in Medicinal Chemistry|August 26, 2015
Epigenetic alterations as a universal feature of cancer hallmarks and a promising target for personalized treatmentsMichael Schnekenburger, Cristina Florean, Mario Dicato, et al.Pageof 7